Yesterday I attended LSPN's spring North America meeting, and what a stimulating and valuable event it was. Gathered together was a formidable line up of in-house counsel and private practitioners with the aim of sharing knowledge and insights into the most important issues currently facing the protection of IP in the life science field.
The day included panel discussions on global patent enforcement strategy, the strategic options for protecting technology in the field of cancer immunotherapies and the implications for brands and generic companies of the incoming tide of biosimilars. The day further included interactive roundtable discussions on various current headline topics, each of which provided unique insights and provoked lively debate.
The topics covered were diverse, but within the immunotherapy and biologics space it was a common theme that the most effective protection for these cutting edge therapies and the best means to mitigate the challenge of biosimilars is to build a patent filing and lifecycle strategy that is fully aligned with data exclusivity rights and other regulatory procedures, trade secrets and marketing/education campaigns. In other words, now more than ever, companies working in these areas must adopt holistic approaches to protecting their IP assets.
The next LSPN meeting is in San Francisco in October and a London meeting is scheduled in November. Well worth attending if you can.
To view the full article, please click here
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
